RAPT Therapeutics, Inc (RAPT:NASDAQ)
$58.02 0.04 (0.069%)
Analysed RAPT Therapeutics, Inc (RAPT:NASDAQ) News Sources
Is It Too Late to Buy GSK After a 46% Share Price Jump?
08-03-2026
247wallst.com
GSK RAPT Acquisition Adds Food Allergy Asset To Immunology Growth Story
07-03-2026
yahoo.com
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp 3 Month Share Price Surge
01-03-2026
yahoo.com
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
25-02-2026
fool.com
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
25-02-2026
fool.com
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
25-02-2026
fool.com
GSK to buy Canada's 35Pharma for $950 million
25-02-2026
yahoo.com
Citi lifts GSK target price but keeps neutral stance after rally
09-02-2026
proactiveinvestors.com
GSK Extends RSV Reach And Adds Food Allergy Assets With RAPT Deal
30-01-2026
yahoo.com
Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp Share Price Surge
23-01-2026
yahoo.com
What is the current price of RAPT Therapeutics, Inc (RAPT:NASDAQ)?
The current price of RAPT Therapeutics, Inc (RAPT:NASDAQ) is $58.02.
RAPT Therapeutics, Inc (RAPT:NASDAQ) absolute price change since previous trading day?
The absolute price change of RAPT Therapeutics, Inc (RAPT:NASDAQ) since the previous trading day is $0.04.
RAPT Therapeutics, Inc (RAPT:NASDAQ) percentage price change since previous trading day?
The percentage price change of RAPT Therapeutics, Inc (RAPT:NASDAQ) since the previous trading day is 0.069%.
What is the most recent average sentiment score for RAPT Therapeutics, Inc (RAPT:NASDAQ)?
The most recent average sentiment score for RAPT Therapeutics, Inc (RAPT:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for RAPT Therapeutics, Inc (RAPT:NASDAQ)?
The most recent sentiment for RAPT Therapeutics, Inc (RAPT:NASDAQ) is .
SEC-8K** Filing Available For RAPT Therapeutics, Inc (RAPT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.